Evotec SE ADR

NASDAQ EVO

Data sourced from iex and EODHD
Download Data

Evotec SE ADR Non-Cash Items (Other) 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 225.16%

Evotec SE ADR Non-Cash Items (Other) 2 year CAGR is 225.16% for the Trailing 12 Months (TTM) ending March 31, 2024, a 60.93% change year over year. Non-Cash Items (Other) are non-cash expenses or gains that impact a company's financial statements, excluding depreciation and amortization. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Evotec SE ADR Non-Cash Items (Other) for the Trailing 12 Months (TTM) ending March 31, 2023 was EUR 184.35 M, a 1,103.77% change year over year.
  • Evotec SE ADR Non-Cash Items (Other) for the Trailing 12 Months (TTM) ending March 31, 2022 was EUR 15.31 M, a -52.18% change year over year.
  • Evotec SE ADR Non-Cash Items (Other) for the Trailing 12 Months (TTM) ending March 31, 2021 was EUR 32.03 M, a -56.46% change year over year.
  • Evotec SE ADR Non-Cash Items (Other) for the Trailing 12 Months (TTM) ending March 31, 2020 was EUR 73.55 M, a 908.56% change year over year.
NASDAQ: EVO

Evotec SE ADR

CEO Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.
IPO Date Dec. 4, 2009
Location Germany
Headquarters Essener Bogen 7, Hamburg, Germany, 22419
Employees 5,055
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Similar companies

EGRX

Eagle Pharmaceuticals Inc

NA

NA

PAHC

Phibro Animal Health Corporation

NA

NA

RGC

Regencell Bioscience Holdings Ltd

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email